logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo merck_oncology

ESMO 2017 : Adjuvant therapy with nivolumab superior to ipilimumab in surgically resected stage III and IV melanoma according to CheckMate 238 trial

The 18-months interim analysis shows a moderate benefit in terms of relapse-free survival with much fewer side effects and therapy termination.